RARE earnings date and last-quarter result: last quarter miss, P/E -4.52. Updated 2026-07-23.
Ultragenyx Pharmaceutical (RARE) Research Hub
Ultragenyx Pharmaceutical (RARE) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 16.08 USD (+2.75%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -4.52, market cap 2.71B. This hub links to the full technical, earnings and options research available for RARE.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 16.08 USD (+2.75%) |
| 52-week range | 12.73 USD – 36.57 USD |
| Trend regime | Range |
| 14-day RSI | 66.7 (Bullish) |
| Trailing P/E | -4.52 |
| Market cap | 2.71B |
| Dividend yield | 0.00% |
Available research for RARE
Covered Call on RARE: how it works, illustrative setup around the real 16.08 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on RARE: how it works, illustrative setup around the real 16.08 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on RARE: how it works, illustrative setup around the real 16.08 USD price, max profit/loss, breakeven and when to use it. Educational.
RARE technical analysis: range, last 16.08 USD, RSI 66.7, 52w range 12.73 USD–36.57 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is RARE in?
Ultragenyx Pharmaceutical (RARE) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is RARE in an uptrend or downtrend?
As of 2026-10-26, RARE is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is RARE's trailing P/E ratio?
RARE's trailing P/E is -4.52, with a market cap of 2.71B. See the earnings research page for full valuation detail.